|
A4: Establish VO2 standards for successful completion of mission tasks.
|
|
A6: Develop pre-flight, in-flight, and post-flight evaluations to determine if VO2 standards are met.
|
|
A7: Develop the most efficient and effective exercise program for the maintenance of VO2 standards.
|
|
A9: Identify and validate exploration countermeasure hardware for the maintenance of VO2 standards.
|
|
Acute - 1: Determine the dose response for acute effects (focusing on effects that are evident at space-relevant doses) induced by SPE-like radiation, including synergistic effects arising from other spaceflight factors (e.g. altered gravity (microgravity), stress, altered immune function, or other) that modify and/or enhance the biological response.
|
|
Acute - 2: What quantitative procedures or theoretical models are needed to extrapolate molecular, cellular, or animal results to predict acute radiation risks in astronauts? How can human epidemiology data best support these procedures or models?
|
|
Acute - 4: What are the probabilities of hereditary, fertility, and sterility effects from space radiation?
|
|
Acute - 5: What are the optimal SPE alert and dosimetry technologies? (Closed. Technology maturation transferred to Advanced Exploration Systems)
|
|
Acute - 6: What are the most effective shielding approaches to mitigate acute radiation risks, how do we know, and implement? (Closed. Transferred to Operations)
|
|
Acute - 7: What are the most effective biomedical or dietary countermeasures to mitigate acute radiation risks?
|
|
Acute - 8: How can Probabilistic risk assessment be applied to SPE risk evaluations for EVA, and combined EVA+IVA exposures ?
|
|
AEH 1: What are the unique properties of lunar dust that affect physiology? (Closed)
|
|
AEH 2: What is the toxicity of lunar dust in the respiratory system? (Closed)
|
|
AEH 4: What is the dermal and ocular toxicity of lunar dust? (Closed)
|
|
AEH 5: What are the permissible exposure limits for inhalation of lunar dust? (Closed)
|
|
AEH Watch Item/NSBRI Research: What are the effects of lunar gravity on permissible exposure limits for inhalation of lunar dust? (Closed)
|
|
B16: Can inhibitors of stone formation be sufficiently provided through dietary sources?
|
|
B5: What is the current state of knowledge regarding renal stone formation due to spaceflight?
|
|
B6: What are the contributing factors other than loss of bone mineral density?
|
|
B7: Is it necessary to increase crew fluid intake and, if possible, to what extent will it mitigate stone formation?
|
|
B8: Do pharmaceuticals work effectively in spaceflight to prevent renal stones?
|
|
B9: What is the frequency of post-flight stone formation; the incidence and types of stones; and the time course of stone formation? How does stone formation correlate with food intake and hydration status?
|
|
BMed1: We need to identify and validate countermeasures that promote individual behavioral health and performance during exploration class missions.
|
|
BMed2: We need to identify and validate measures to monitor behavioral health and performance during exploration class missions to determine acceptable thresholds for these measures.
|
|
BMed3: We need to identify and quantify the key threats to and promoters of mission relevant behavioral health and performance during autonomous, long duration and/or long distance exploration missions.
|